In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 3, 2013, Pages 138-144

  Delvadia, Renishkumar ^a   Hindle, Michael ^a   Worth Longest, P ^a   Byron, Peter R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

aerosol testing; airway model; DPI; gamma scintigraphy; in vitro testing; IVIVC; method validity

Indexed keywords

AEROLIZER; BUDESONIDE; DISKHALER; FORMOTEROL FUMARATE; HANDIHALER; SALBUTAMOL; TIOTROPIUM BROMIDE; TURBUHALER; UNCLASSIFIED DRUG; ZANAMIVIR;

AEROSOL; AIRFLOW; ARTICLE; CLINICAL ASSESSMENT; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; FLOW RATE; GAMMA SCINTIGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; SCINTIGRAPHY; STOICHIOMETRY;

ADULT; ANIMALS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LUNG; MODELS, ANATOMIC; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84878413637     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.0975     Document Type: Article

References (26)

1. Newman SP, and Chan HK: In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv. 2008;21:77-84.
2. Newman SP, Wilding IR, and Hirst PH: Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm. 2000; 208:49-60.
3. Byron PR, Hindle M, Lange CF, Longest PW, McRobbie D, Oldham MJ, Olsson B, Thiel CG, Wachtel H, and Finlay WH: In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 2:S59-S69.
4. Delvadia RR, Longest PW, and Byron PR: In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J Aerosol Med Pulm Drug Deliv. 2012;25:32-40.
5. Xi J, and Longest PW: Transport and deposition of microaerosols in realistic and simplified models of the oral airway. Ann Biomed Eng. 2007;35:560-581.
6. Yeh HC, and Schum GM: Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol. 1980;42:461-480.
7. Tian G, Longest PW, Su G, Walenga RL, and Hindle M: Development of a stochastic individual path (SIP) model for predicting the tracheobronchial deposition of pharmaceutical aerosols: effects of transient inhalation and sampling the airways. J Aerosol Sci. 2011;42:781-799.
8. Longest PW: Adult Upper Airway Models. 2011. Available at: http://www.rddonline.com/resources/tools/models.php. Accessed August 17, 2011.
9. Byron PR, Delvadia RR, Longest PW, and Hindle M: Stepping into the trachea with realistic physical models: uncertainties in regional drug deposition from powder inhalers. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young, (eds). Proceedings of Respiratory Drug Delivery 2010, Vol. I. Davis Healthcare International Publishing, River Grove, IL, and www.rddonline.com; pp. 215-224, 2010.
10. Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G, and Scheuch G: Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007;47: 1335-1341.
11. International Committee for Harmonisation: Q2B Validation of Analytical Procedures: Methodology. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceCompliance RegulatoryInformation/Guidances/UCM073384.pdf. Accessed August 8, 2012.
12. Meyer T, Brand P, Ehlich H, Kobrich R, Meyer G, Riedinger F, Sommerer K, Weuthen T, and Scheuch G: Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med. 2004;17:43-49.
13. Vidgren M, Arppe J, Vidgren P, Vainio P, Silvasti M, and Tukiainen H: Pulmonary deposition of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose powder inhaler. STP Pharma Sci. 1994;4:29-32.
14. Borgström L, Bondesson E, Morén F, Trofast E, and Newman S: Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69-73.
15. Cass LM, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, and Bye A: Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36 Suppl 1:21-31.
16. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, and Witek TJ: Effective delivery of particles with the HandiHaler-Dry Powder Inhalation System over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14:309-315.
17. Newman SP, Pitcairn GR, Adkin DA, Vidgren MT, and Silvasti M: Comparison of beclomethasone dipropionate delivery by Easyhaler-Dry Powder Inhaler and pMDI plus large volume spacer. J Aerosol Med. 2001;14:217-225.
18. Son Y-J, and McConville JT: Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm. 2008;34:948-959.
19. Newman S, and Peart J: Dry powder inhalers. In: S Newman, P Anderson, P Byron, R Dalby, and J Peart, (eds). Respiratory Drug Delivery: Essential Theory and Practice. RDD Online/Virginia Commonwealth University, Richmond, VA; pp. 257-307, 2009.
20. Islam N, and Gladki E: Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm. 2008;360:1-11.
21. Newman SP, Pitcairn GR, Hirst PH, Bacon RE, O'Keefe E, Reiners M, and Hermann R: Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J. 2000;16:178-183.
22. Dolovich MB: Practical aspects of imaging techniques employed to study aerosol deposition and clearance. In: AJ Hickey, (ed). Pharmaceutical inhalation aerosol technology, Vol. 134. Marcel Dekker, Inc., New York; pp. 171-213, 2004.
23. Kamiya A, Sakagami M, and Byron PR: Cascade impactor practice for a high dose dry powder inhaler at 90 L/min: NGI versus modified 6-stage and 8-stage ACI. J Pharm Sci. 2009;98:1028-1039.
24. Delvadia RR, Byron PR, Longest PW, and Hindle M: In vitro prediction of regional drug deposition from dry powder inhalers. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young, (eds). Proceedings of Respiratory Drug Delivery 2010, Vol. III. Davis Healthcare International Publishing, River Grove, IL, and www.rddonline.com; pp. 907-912, 2010.
25. Akapo SO, and Asif M: Validation of a RP-HPLC method for the assay of formoterol and its related substances in formoterol fumarate dihydrate drug substance. J Pharm Biomed. 2003;33:935-945.
26. Martin T, Bandi N, Shulz R, Roberts C, and Kompella U: Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech. 2002;3:16-26.